Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage
- PMID: 20809188
- PMCID: PMC3012204
- DOI: 10.1007/s12028-010-9435-1
Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage
Abstract
Aneurysmal subarachnoid hemorrhage (SAH) is associated with numerous "delayed neurological deficits" (DNDs) that have been attributed to multiple pathophysiological mechanisms, including ischemia, microthrombosis, free radical damage, inflammation, and vascular remodeling. To date, effective prophylactic therapy for SAH-induced DNDs has been elusive, due perhaps to the multiplicity of mechanisms involved that render typical, single-agent therapy seemingly futile. We hypothesized that heparin, which has multiple underappreciated salutary effects, might be useful as a multitargeted prophylactic agent against SAH-induced DNDs. We performed a comprehensive review of the literature to evaluate the potential utility of heparin in targeting the multiple pathophysiological mechanisms that have been identified as contributing to SAH-induced DNDs. Our literature review revealed that unfractionated heparin can potentially antagonize essentially all of the pathophysiological mechanisms known to be activated following SAH. Heparin binds >100 proteins, including plasma proteins, proteins released from platelets, cytokines, and chemokines. Also, heparin complexes with oxyhemoglobin, blocks the activity of free radicals including reactive oxygen species, antagonizes endothelin-mediated vasoconstriction, smooth muscle depolarization, and inflammatory, growth and fibrogenic responses. Our review suggests that the use of prophylactic heparin following SAH may warrant formal study.
Similar articles
-
Optimizing subarachnoid fibrinolytic therapy for aneurysmal subarachnoid hemorrhage.World Neurosurg. 2010 Jun;73(6):622-3. doi: 10.1016/j.wneu.2010.05.046. World Neurosurg. 2010. PMID: 20934139 No abstract available.
-
Tetramethylpyrazine Nitrone Reduces Oxidative Stress to Alleviate Cerebral Vasospasm in Experimental Subarachnoid Hemorrhage Models.Neuromolecular Med. 2019 Sep;21(3):262-274. doi: 10.1007/s12017-019-08543-9. Epub 2019 May 27. Neuromolecular Med. 2019. PMID: 31134485
-
NLRP3 inhibition attenuates early brain injury and delayed cerebral vasospasm after subarachnoid hemorrhage.J Neuroinflammation. 2021 Jul 20;18(1):163. doi: 10.1186/s12974-021-02207-x. J Neuroinflammation. 2021. PMID: 34284798 Free PMC article.
-
Effect of statin treatment on vasospasm-related morbidity and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.J Neurosurg. 2017 Aug;127(2):291-301. doi: 10.3171/2016.5.JNS152900. Epub 2016 Oct 7. J Neurosurg. 2017. PMID: 27715439
-
Delayed ischemia after subarachnoid hemorrhage: result of vasospasm alone or a broader vasculopathy?Vasc Med. 2007 Aug;12(3):243-9. doi: 10.1177/1358863X07081316. Vasc Med. 2007. PMID: 17848485 Review.
Cited by
-
Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.Transl Stroke Res. 2012 Jul;3(Suppl 1):155-65. doi: 10.1007/s12975-012-0166-9. Epub 2012 Apr 14. Transl Stroke Res. 2012. PMID: 22707992 Free PMC article.
-
Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage.Transl Stroke Res. 2014 Jun;5(3):357-64. doi: 10.1007/s12975-013-0310-1. Epub 2013 Nov 20. Transl Stroke Res. 2014. PMID: 24323729 Review.
-
Glibenclamide for the treatment of ischemic and hemorrhagic stroke.Int J Mol Sci. 2015 Mar 4;16(3):4973-84. doi: 10.3390/ijms16034973. Int J Mol Sci. 2015. PMID: 25749474 Free PMC article. Review.
-
Association between external ventricular drain removal or replacement and prophylactic anticoagulation in patients with aneurysmal subarachnoid hemorrhage: a propensity-adjusted analysis.Acta Neurochir (Wien). 2023 Jul;165(7):1841-1846. doi: 10.1007/s00701-023-05651-1. Epub 2023 Jun 10. Acta Neurochir (Wien). 2023. PMID: 37301800
-
Neuroinflammation and Microvascular Dysfunction After Experimental Subarachnoid Hemorrhage: Emerging Components of Early Brain Injury Related to Outcome.Neurocrit Care. 2019 Oct;31(2):373-389. doi: 10.1007/s12028-019-00710-x. Neurocrit Care. 2019. PMID: 31012056 Free PMC article. Review.
References
-
- Bederson JB, Connolly ES, Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40:994–1025. - PubMed
-
- Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;354:387–96. - PubMed
-
- Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007;3:256–63. - PubMed
-
- Rothoerl RD, Ringel F. Molecular mechanisms of cerebral vasospasm following aneurysmal SAH. Neurol Res. 2007;29:636–42. - PubMed
-
- Provencio JJ, Vora N. Subarachnoid hemorrhage and inflammation: bench to bedside and back. Semin Neurol. 2005;25:435–44. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical